Can ARNI Prevent Doxorubicin-Induced Cardiotoxicity? (original) (raw)

The letter critiques a previous study by Dindaş et al. regarding the protective effects of Sacubitril/Valsartan (SAC/VAL) against doxorubicin-induced cardiotoxicity in a murine model. Key concerns raised include the lack of quantitative data in histological evaluations, absence of imaging methods to assess left ventricular function, and a mischaracterization of reactive oxygen species (ROS) as the primary cause of doxorubicin toxicity. The critique requests clarification on SAC/VAL's interaction with topoisomerase 2 β (TOPO2β) and emphasizes the need for a more nuanced understanding of the mechanisms underlying doxorubicin cardiotoxicity.